Close
FINDING CURES TOGETHER<sup>SM</sup>

11th AACR-JCA Joint Conference on Breakthroughs in Cancer Research: Biology to Precision Medicine

Friday, Feb. 8, 2019

Welcome and Keynote Session
Session Chairs: Elaine R. Mardis, Nationwide Children’s Hospital, Columbus, Ohio, USA, and Hitoshi Nakagama, National Cancer Center, Tokyo, Japan
6:30-8 p.m.

Cancer genomics: Discovery to clinical translation
Elaine R. Mardis

Regulatory T cells in tumor immunity
Shimon Sakaguchi, Osaka University, Osaka, Japan



Opening Reception
8-9:30 p.m.
 

Saturday, Feb. 9, 2019

Continental Breakfast and Networking Roundtables
7-8 a.m.


Plenary Session 1: Tumor Microenvironment
Session Chairs: Kohei Miyazono, The University of Tokyo, Tokyo, Japan, and Raghu Kalluri, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
8-9:30 a.m.

Exploiting the biology of exosomes for diagnosis and treatment of cancer
Raghu Kalluri

Role of actin dynamics in cell fate plasticity of microenvironmental cells
Hideyuki Saya, Keio University School of Medicine, Tokyo, Japan

Neutrophil extracellular traps activated during inflammation awaken dormant cancer cells
Mikala Egeblad, Cold Spring Harbor Laboratory Cancer Center, Cold Spring Harbor, New York


Break
9:30-10 a.m.


Plenary Session 2: Cancer Precision Medicine, Prevention, Interception, and Early Detection
Session Chairs: Nickolas Papadopoulos, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA, and Yoshinori Murakami, The University of Tokyo, Tokyo, Japan
10-11:30 a.m.

Non-invasive earlier detection of cancer
Nickolas Papadopoulos

Construction of cancer genomic medicine platform in Japan
Hiroyuki Mano, National Cancer Center Research Institute, Tokyo, Japan

Genome-wide analysis of plasma cell-free DNA for cancer detection
Geoffrey R. Oxnard, Dana-Farber Cancer Institute, Boston, Massachusetts


Free Time
11:30 a.m.-4 p.m.


Plenary Session 3: Heterogeneity, Clonal Evolution, and Big Data
Session Chairs: Yoshio Miki, Tokyo Medical and Dental University, Tokyo, Japan, and Samuel Aparicio, British Columbia Cancer Agency, Vancouver, BC, Canada
4-5:30 p.m.

Clonal dynamics and cellular fitness in cancer to single cell resolution
Samuel Aparicio

Strong potential for combinatorial approaches involving TGF-b kinase inhibitor: considerable utility in a wide variety of cancers
Seong-Jin Kim, Seoul National University, Seoul, South Korea

Quantifying clonal evolution through treatment and metastasis
Christina Curtis, Stanford University, Stanford, California


5:30-7:30 p.m.


Top of page
 

Sunday, Feb. 10, 2019

Continental Breakfast and Networking Roundtables
7-8 a.m.


Plenary Session 4: Metabolism
Session Chairs: Lewis C. Cantley, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York, USA, and Takashi Takahashi, Aichi Cancer Center, Aichi, Japan
8-9:30 a.m.

Next-generation proteomics unveils a global landscape of cancer metabolism: Discovery of the "second" Warburg effect
Kei-ichi Nakayama, Kyushu University, Fukuoka, Japan

PI3-kinase and cancer
Lewis C. Cantley

NRF2 addiction in cancer cells and its impact on cancer metabolism
Hozumi Motohashi, Tohoku University, Sendai, Japan


Break
9:30-10 a.m.


Plenary Session 5: Epigenetics
Session Chairs: Wataru Yasui, Hiroshima University, Hiroshima, Japan, and Mathieu Lupien, Princess Margaret Cancer Centre, Toronto, Canada
10-11:30 a.m.

Precision cancer risk diagnosis based upon epigenomic record of the life
Toshikazu Ushijima, National Cancer Center Research Institute, Tokyo, Japan

Primary glioblastoma arise from a heterogeneous population of cancer stem cells defined by chromatin state
Mathieu Lupien

ATAC-seq analysis reveals epigenomic heterogeneity in breast cancer
Reo Maruyama, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan


Free Time

11:30 a.m.-4 p.m.



Plenary Session 6: Immunotherapy
Session Chairs: Yutaka Kawakami, Keio University, Tokyo, Japan, and Cassian Yee, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
4-5:30 p.m.

Potent anti-tumor effects of IL-7/CCL19-producing CAR-T cells against solid tumors
Koji Tamada, Yamaguchi University, Yamaguchi, Japan

Genetic alterations involving PD-1 ligands in virus-associated lymphomas
Keisuke Kataoka, National Cancer Center Research Institute, Tokyo, Japan

Adoptive T cell therapy: Impersonalized precision medicine
Cassian Yee


Poster Session B  
5:30-7:30 p.m.


Top of page


Monday, Feb. 11, 2019

Continental Breakfast
7-8 a.m.


Plenary Session 7: Microbiome
Session Chairs: Takuro Nakamura, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan, and Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
8-9:30 a.m.

The role of the microbiome in response to cancer therapy
Jennifer A. Wargo

The impact of Helicobacter pylori infection on gastric carcinogenesis
Masanori Hatakeyama, The University of Tokyo, Tokyo, Japan

Microbial regulation of tumor elicited inflammation
Sergei Grivennikov, Fox Chase Cancer Center, Philadelphia, Pennsylvania


Break
9:30-10 a.m.


Plenary Session 8: Engineering, Nanotechnology, and Imaging
Session Chairs: Daniel A. Heller, Memorial Sloan Kettering Cancer Center, New York, New York, USA, and Masanobu Oshima, Cancer Research Institute, Kanazawa University, Ishikawa, Japan
10-11:30 a.m.

Macrocyclic pseudo-natural peptides for anti-cancer therapies
Hiroaki Suga, The University of Tokyo, Tokyo, Japan

Nanomedicines to improve the therapeutic index of precision medicines
Daniel A. Heller

Application of tissue clearing technology in cancer research
Kei Takahashi, The University of Tokyo, Tokyo, Japan


Free Time
11:30 a.m.-4 p.m.


Plenary Session 9: Liquid Biopsy
Session Chairs: Fuyuki Ishikawa, Kyoto University, Kyoto, Japan, and Alberto Bardelli, University of Turin - Candiolo Cancer Institute IRCCS, Candiolo, Italy
4-5:30 p.m.

The emerging role of exosome in cancer diagnostic and therapeutics
Takahiro Ochiya, Tokyo Medical University; National Cancer Center Research Institute, Tokyo, Japan

Inactivation of DNA repair to improve immune surveillance and restrict cancer growth
Alberto Bardelli

A proteome-wide catalog of viable tissue-derived exosomes, toward development of cancer liquid biopsy
Koji Ueda, Japanese Foundation for Cancer Research, Tokyo, Japan



Poster Session C 
5:30-7:30 p.m.


Top of page


Tuesday, Feb. 12, 2019

Continental Breakfast
7-8 a.m.

Plenary Session 10: Drug Resistance
Session Chairs: Alan Ashworth, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA, and Naoya Fujita, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan
8-9:30 a.m.

Mechanism of the intrinsic resistance and emergence of tolerant cells to osimertinib in EGFR mutated lung cancer
Seiji Yano, Cancer Research Institute, Kanazawa University, Ishikawa, Japan

Synthetic lethal approaches to cancer therapy
Alan Ashworth

Cellular diversity by genetic and non-genetic alteration in cancer induces acquired resistance in NSCLC
Ryohei Katayama, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan


Break
9:30-10 a.m.


Plenary Session 11: Novel Targets and Drug Discovery
Session Chairs: Atsushi Ochiai, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba and Tokyo, Japan, and Kevan M. Shokat, University of California San Francisco and Howard Hughes Medical Institute, San Francisco, California, USA
10-11:30 a.m.

Chemical strategies for discovering direct inhibitors of K-Ras and other oncogenic GTPases
Kevan M. Shokat

Telomere as the starting point of anticancer drug discovery
Hiroyuki Seimiya, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan

Structure and function of mammalian SWI/SNF chromatin remodeling complexes in human cancer
Cigall Kadoch, Dana-Farber Cancer Institute, Boston, Massachusetts


Free Time
11:30 a.m.-3:30 p.m.


Plenary Session 12: Translational and Clinical Research and Clinical Trials
Session Chairs: Riccardo Dalla-Favera, Columbia University Institute for Cancer Genetics, New York, New York, USA, and Hiroyuki Seimiya, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan
3:30-5:30 p.m.

Drug repurposing for diffuse large B-cell lymphoma
Riccardo Dalla-Favera

Metabolic regulation of stemness in hematopoietic malignancy
Atsushi Hirao, Cancer Research Institute, Kanazawa University, Ishikawa, Japan

Targeting oncogene dependencies in metastatic breast cancer: A clinical and translational perspective
Dejan Juric, Massachusetts General Hospital Cancer Center, Boston, Massachusetts

Phase II clinical trial of oncolytic herpes virus G47Δ in patients with glioblastoma
Tomoki Todo, The University of Tokyo, Tokyo, Japan


Poster Session D  
5:30-7:30 p.m.

Top of page